Autres langues Novo Nordisk A/S

Actions

NOVO B

DK0062498333

Produits pharmaceutiques

PEA

Marché Fermé - Nasdaq Copenhagen Autres places de cotation 17:20:00 13/06/2025			Varia. 5j.	Varia. 1 janv.
516,20 ^DKK	-0,58 %		+5,27 %	-17,30 %

00:39	Le médicament expérimental contre l'obésité d'Eli Lilly montre une perte de poids de plus de 11 % lors des premiers essais	RE
13/06	Odin Norden a progressé de 3,16 % en mai – saison positive pour les sociétés du portefeuille	FW

Autres langues

Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	00:39
Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing…	13/06
Schwächer - "DAX kommt mit blauem Auge davon"	13/06
Novo Nordisk salta a la última fase de desarrollo del nuevo medicamento contra la obesidad -- Market Talk	13/06
Novo Nordisk Surpasses SAP to Regain Europe's Most Valuable Listed Company Title	13/06
Novo Nordisk regains crown as Europe's most valuable company	13/06
Novo Nordisk regains crown as Europe's most valuable company	13/06
Novo Nordisk wieder wertvollstes europäisches Unternehmen	13/06
Novo Nordisk: amycretin progresses to Phase 3	13/06
Novo Nordisk to Launch Late-stage Development of Amycretin Weight Management Treatment	13/06
Sector Update: Health Care Stocks Higher Late Afternoon	12/06
Sector Update: Health Care	12/06
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year	12/06
Novo Nordisk plans to start late-stage trials of obesity drug amycretin next year	12/06
Novo Nordisk Plans Phase 3 Clinical Development of Amycretin for Weight Management	12/06
Novo Nordisk gaat nieuw afslankmiddel verder ontwikkelen	12/06
Novo Nordisk plans to start late-stage trials for experimental obesity drug amycretin	12/06
Novo Nordisk Says Planning To Initiate A Phase 3 Development Programme With Amycretin For Adults With Overweight Or Obesity During Q1 Of 2026	12/06
Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development	12/06
Novo Nordisk to Advance Subcutaneous and Oral Amycretin for Weight Management into Phase 3 Clinical Development	12/06
Deep Apple Therapeutics Announces Collaboration with Novo Nordisk to Discover and Develop Oral Therapeutics for Cardiometabolic Diseases	12/06
India's OneSource eyes weight-loss drug boost to order book	12/06
Allarity Therapeutics, Inc Announces Changes to Board of Directors	11/06
Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple	11/06
Top Midday Stories: Trump Says China Trade Deal 'Done;' US May Inflation Lower Than Expected	11/06